InstitutionMD Anderson
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lee EQ, Selig W, Meehan C, Bacha J, Barone A, Bloomquist E, Chang SM, de Groot JF, Galanis E, Hassan I, Kalidas C, Khasraw M, Kvedar JC, Lassman AB, Puduvalli V, Sahebjam S, Schwamm LH, Tamir S, Welch M, Yung WKA, Zadeh G, Arons D, Wen PY. Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. Neuro Oncol. 2021 08 02; 23(8):1252-1260. PMID: 33822177.
      Citations:    Fields:    Translation:Humans
    2. Brown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer MF, Ghia AJ, Sulman EP, Penas-Prado M, de Groot JF, Heimberger AB, Wang J, Armstrong TS, Gilbert MR, Guha-Thakurta N, Wefel JS. A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. Neuro Oncol. 2021 08 02; 23(8):1337-1347. PMID: 33647972.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    3. Barekatain Y, Ackroyd JJ, Yan VC, Khadka S, Wang L, Chen KC, Poral AH, Tran T, Georgiou DK, Arthur K, Lin YH, Satani N, Ballato ES, Behr EI, deCarvalho AC, Verhaak RGW, de Groot J, Huse JT, Asara JM, Kalluri R, Muller FL. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine. Nat Commun. 2021 07 09; 12(1):4228. PMID: 34244484.
      Citations:    Fields:    Translation:HumansCells
    4. Ellingson BM, Patel K, Wang C, Raymond C, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Schlossman J, Rizvi S, Cohen YC, Lowenton-Spier N, Minei TR, Shmueli SF, Wen PY, Cloughesy TF. Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab082. PMID: 34377989.
    5. Mandel JJ, Youssef M, Yust-Katz S, Patel AJ, Jalali A, Li Z, Wu J, Ludmir EB, de Groot JF. IDH mutation status and the development of venous thromboembolism in astrocytoma patients. J Neurol Sci. 2021 Aug 15; 427:117538. PMID: 34146775.
      Citations:    Fields:    Translation:Humans
    6. Al Feghali KA, Randall JW, Liu DD, Wefel JS, Brown PD, Grosshans DR, McAvoy SA, Farhat MA, Li J, McGovern SL, McAleer MF, Ghia AJ, Paulino AC, Sulman EP, Penas-Prado M, Wang J, de Groot J, Heimberger AB, Armstrong TS, Gilbert MR, Mahajan A, Guha-Thakurta N, Chung C. Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab073. PMID: 34337411.
    7. Wu S, Li X, Gao F, de Groot JF, Koul D, Yung WKA. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol. 2021 06 01; 23(6):920-931. PMID: 33433610.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    8. Veselka B, Locher H, de Groot JCMJ, Davies GR, Snoeck C, Kootker LM. Strontium isotope ratios related to childhood mobility: Revisiting sampling strategies of the calcined human pars petrosa ossis temporalis. Rapid Commun Mass Spectrom. 2021 Apr 15; 35(7):e9038. PMID: 33370492.
      Citations: 1     Fields:    
    9. Mohan R, Liu AY, Brown PD, Mahajan A, Dinh J, Chung C, McAvoy S, McAleer MF, Lin SH, Li J, Ghia AJ, Zhu C, Sulman EP, de Groot JF, Heimberger AB, McGovern SL, Grassberger C, Shih H, Ellsworth S, Grosshans DR. Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro Oncol. 2021 02 25; 23(2):284-294. PMID: 32750703.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    10. Majd NK, Yap TA, Koul D, Balasubramaniyan V, Li X, Khan S, Gandy KS, Yung WKA, de Groot JF. The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab015. PMID: 33738447.
    11. Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2021 02 15; 27(4):1048-1057. PMID: 33199490.
      Citations: 10     Fields:    
    12. van Beelen ESA, van der Valk WH, de Groot JCMJ, Hensen EF, Locher H, van Benthem PPG. Migration and fate of vestibular melanocytes during the development of the human inner ear. Dev Neurobiol. 2020 11; 80(11-12):411-432. PMID: 33075185.
      Citations: 1     Fields:    
    13. Park SY, Mittal S, Dong J, Jeong K, Martinez-Ledesma E, Piao Y, Khan S, Henry V, Verhaak RG, Majd N, Balasubramaniyan V, de Groot JF. Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors. Am J Cancer Res. 2020; 10(11):3765-3783. PMID: 33294266.
      Citations: 1     
    14. Ferguson SD, Hodges TR, Majd NK, Alfaro-Munoz K, Al-Holou WN, Suki D, de Groot JF, Fuller GN, Xue L, Li M, Jacobs C, Rao G, Colen RR, Xiu J, Verhaak R, Spetzler D, Khasraw M, Sawaya R, Long JP, Heimberger AB. A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdaa146. PMID: 33426529.
    15. Aaroe AE, Majd N, Weathers SP, de Groot JF. Potential neurologic and oncologic implications of the novel coronavirus. Neuro Oncol. 2020 07 07; 22(7):1050-1051. PMID: 32296828.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
    16. Barekatain Y, Yan VC, Arthur K, Ackroyd JJ, Khadka S, De Groot J, Huse JT, Muller FL. Robust detection of oncometabolic aberrations by 1H-13C heteronuclear single quantum correlation in intact biological specimens. Commun Biol. 2020 06 25; 3(1):328. PMID: 32587392.
      Citations:    Translation:HumansAnimalsCells
    17. Harrison RA, Tummala S, de Groot J. Neurologic Toxicities of Cancer Immunotherapies: a Review. Curr Neurol Neurosci Rep. 2020 06 08; 20(7):27. PMID: 32514633.
      Citations: 1     Fields:    Translation:Humans
    18. Berkman AM, Livingston JA, Merriman K, Hildebrandt M, Wang J, Dibaj S, McQuade J, You N, Ying A, Barcenas C, Bodurka D, DePombo A, Lee HJ, de Groot J, Roth M. Long-term survival among 5-year survivors of adolescent and young adult cancer. Cancer. 2020 08 15; 126(16):3708-3718. PMID: 32484922.
      Citations: 4     Fields:    Translation:Humans
    19. Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Ellingson BM, Freedman LS, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Fain Shmueli S, Wen PY. A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro Oncol. 2020 05 15; 22(5):705-717. PMID: 31844890.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    20. Nam JY, Gilbert A, Cachia D, Mandel J, Fuller GN, Penas-Prado M, de Groot J, Kamiya-Matsuoka C. Pineal parenchymal tumor of intermediate differentiation: a single-institution experience. Neurooncol Pract. 2020 Dec; 7(6):613-619. PMID: 33312675.
      Citations: 1     
    21. Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577. PMID: 32299815.
      Citations: 5     Fields:    
    22. de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549. PMID: 31755915.
      Citations: 23     Fields:    Translation:HumansCells
    23. Patel RR, Verma V, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Mainwaring W, Augustyn A, Fuller CD, Sulman EP, Yeboa DN, Chung CC, McAleer MF, Li J, Yoshor D, de Groot JF, Mandel JJ, Ludmir EB. Exclusion of patients with brain metastases from cancer clinical trials. Neuro Oncol. 2020 04 15; 22(4):577-579. PMID: 31900480.
      Citations: 1     Fields:    Translation:Humans
    24. Khan S, Mittal S, McGee K, Alfaro-Munoz KD, Majd N, Balasubramaniyan V, de Groot JF. Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance. Int J Mol Sci. 2020 Mar 13; 21(6). PMID: 32182988.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    25. Beccaria K, Sabbagh A, de Groot J, Canney M, Carpentier A, Heimberger AB. Blood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors. J Neurooncol. 2021 Jan; 151(1):65-73. PMID: 32112296.
      Citations: 8     Fields:    
    26. Wei J, Chen P, Gupta P, Ott M, Zamler D, Kassab C, Bhat KP, Curran MA, de Groot JF, Heimberger AB. Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2020 02 20; 22(2):180-194. PMID: 31679017.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    27. Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020 Apr; 1:423-436. PMID: 33521652.
      Citations: 23     
    28. Kamiya-Matsuoka C, Hamza MA, de Groot JF. Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma. J Clin Neurosci. 2020 Apr; 74:36-40. PMID: 31982279.
      Citations:    Fields:    Translation:Humans
    29. Majd N, Dasgupta P, de Groot J. Immunotherapy for Neuro-Oncology. Adv Exp Med Biol. 2020; 1244:183-203. PMID: 32301015.
      Citations: 2     Fields:    Translation:Humans
    30. Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46. PMID: 31873309.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    31. Wu S, Gao F, Zheng S, Zhang C, Martinez-Ledesma E, Ezhilarasan R, Ding J, Li X, Feng N, Multani A, Sulman EP, Verhaak RG, de Groot JF, Heffernan TP, Yung WKA, Koul D. EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clin Cancer Res. 2020 03 15; 26(6):1395-1407. PMID: 31852834.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    32. Majd N, Kamiya-Matsuoka C, de Groot J. The path forward for anti-programmed cell death-1 therapy in gliomas. Curr Opin Neurol. 2019 12; 32(6):864-871. PMID: 31567548.
      Citations: 1     Fields:    Translation:HumansAnimals
    33. Rogers CL, Won M, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Fogh SE, Youssef E, Deb N, Kwok Y, Robinson CG, Shu HK, Fisher BJ, Panet-Raymond V, McMillan WG, de Groot JF, Zhang P, Mehta MP. High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys. 2020 03 15; 106(4):790-799. PMID: 31786276.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    34. Gammon ST, Pisaneschi F, Bandi ML, Smith MG, Sun Y, Rao Y, Muller F, Wong F, De Groot J, Ackroyd J, Mawlawi O, Davies MA, Gopal YNV, Di Francesco ME, Marszalek JR, Dewhirst M, Piwnica-Worms D. Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo. Cells. 2019 11 21; 8(12). PMID: 31766580.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    35. Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019 12; 576(7785):112-120. PMID: 31748746.
      Citations: 71     Fields:    Translation:HumansCells
    36. Kesler SR, Harrison RA, Petersen ML, Rao V, Dyson H, Alfaro-Munoz K, Weathers SP, de Groot J. Pre-surgical connectome features predict IDH status in diffuse gliomas. Oncotarget. 2019 Nov 05; 10(60):6484-6493. PMID: 31741712.
      Citations: 1     Fields:    
    37. Majd N, Weathers SP, de Groot J. Are we AKT-ually getting closer to making targeted therapy successful in breast cancer brain metastases? Neuro Oncol. 2019 11 04; 21(11):1344-1345. PMID: 31515554.
      Citations:    Fields:    Translation:Humans
    38. Farooqi A, Li J, de Groot J, Yeboa DN. Current Role of Radiation Therapy in the Management of Malignant Central Nervous System Tumors. Hematol Oncol Clin North Am. 2020 02; 34(1):13-28. PMID: 31739940.
      Citations: 2     Fields:    Translation:Humans
    39. Youssef M, Ludmir EB, Mandel JJ, Patel AJ, Jalali A, Treiber J, Wu J, McAleer MF, de Groot JF. Treatment strategies for glioblastoma in older patients: age is just a number. J Neurooncol. 2019 Nov; 145(2):357-364. PMID: 31643011.
      Citations: 3     Fields:    Translation:Humans
    40. Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, Weller M, Reardon DA, Wen PY. Barriers to accrual and enrollment in brain tumor trials. Neuro Oncol. 2019 09 06; 21(9):1100-1117. PMID: 31175826.
      Citations: 13     Fields:    Translation:Humans
    41. Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY. Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 09 01; 85(3):E607-E608. PMID: 31215634.
      Citations: 2     Fields:    
    42. Majd N, de Groot J. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma. Expert Opin Pharmacother. 2019 Sep; 20(13):1609-1624. PMID: 31264484.
      Citations: 3     Fields:    Translation:HumansCells
    43. Robins HI, Eickhoff J, Gilbert MR, Armstrong TS, Shi W, De Groot JF, Schultz CJ, Hunter GK, Valeinis E, Roach M, Youssef EF, Souhami L, Howard SP, Lieberman FS, Herman JG, Zhang P, Mehta MP. The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. Neurooncol Pract. 2019 Dec; 6(6):473-478. PMID: 31832217.
      Citations: 1     
    44. Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer. 2019 05; 112:83-93. PMID: 30951926.
      Citations: 3     Fields:    Translation:Humans
    45. Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K, Verhaak RG, Mills GB, Yung WKA, Weathers SP, de Groot JF. Prospective Clinical Sequencing of Adult Glioma. Mol Cancer Ther. 2019 05; 18(5):991-1000. PMID: 30926639.
      Citations: 2     Translation:HumansCells
    46. Alexander BM, Trippa L, Gaffey S, Arrillaga-Romany IC, Lee EQ, Rinne ML, Ahluwalia MS, Colman H, Fell G, Galanis E, de Groot J, Drappatz J, Lassman AB, Meredith DM, Nabors LB, Santagata S, Schiff D, Welch MR, Ligon KL, Wen PY. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3. PMID: 32914038.
      Citations: 7     
    47. Ludmir EB, Mandel JJ, McAleer MF, de Groot JF. Disparities along the glioblastoma clinical trials landscape. Neuro Oncol. 2019 02 14; 21(2):285-286. PMID: 30476295.
      Citations: 3     Fields:    Translation:Humans
    48. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486. PMID: 30742122.
      Citations: 248     Fields:    Translation:HumansCells
    49. Schomann T, Mezzanotte L, de Groot JCMJ, Löwik CWGM, Frijns JHM, Huisman MA. Imaging Bioluminescent Exogenous Stem Cells in the Intact Guinea Pig Cochlea. Anat Rec (Hoboken). 2020 03; 303(3):427-440. PMID: 30635981.
      Citations:    Fields:    Translation:AnimalsCells
    50. Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750. PMID: 30715997.
      Citations: 26     Fields:    Translation:HumansCellsCTClinical Trials
    51. Mandel JJ, Youssef M, Nam J, Patel AJ, Jalali A, Ludmir EB, Liu D, Wu J, Armstrong G, Huse J, Bondy M, de Groot JF. Effect of health disparities on overall survival of patients with glioblastoma. J Neurooncol. 2019 Apr; 142(2):365-374. PMID: 30671709.
      Citations: 3     Fields:    Translation:Humans
    52. D'Angelo F, Ceccarelli M, Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam DH, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat Med. 2019 01; 25(1):176-187. PMID: 30531922.
      Citations: 49     Fields:    Translation:HumansCells
    53. Schiff D, de Groot JF. Lower-grade gliomas: the wrong target for bevacizumab. Neuro Oncol. 2018 11 12; 20(12):1559-1560. PMID: 30418659.
      Citations:    Fields:    Translation:Humans
    54. Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. 2019 02 01; 125(3):424-433. PMID: 30359477.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    55. Monroy-Gonzalez AG, Tio RA, de Groot JC, Boersma HH, Prakken NH, De Jongste MJL, Alexanderson-Rosas E, Slart RHJA. Long-term prognostic value of quantitative myocardial perfusion in patients with chest pain and normal coronary arteries. J Nucl Cardiol. 2019 12; 26(6):1844-1852. PMID: 30288680.
      Citations: 2     Fields:    Translation:Humans
    56. Ding X, Wang Z, Chen D, Wang Y, Zhao Z, Sun C, Chen D, Tang C, Xiong J, Chen L, Yao Z, Liu Y, Wang X, Cahill DP, de Groot JF, Jiang T, Yao Y, Zhou L. The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study. J Neurooncol. 2018 Dec; 140(3):591-603. PMID: 30206763.
      Citations: 7     Fields:    Translation:Humans
    57. Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol. 2018 09 03; 20(10):1411-1418. PMID: 29660005.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    58. Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250. PMID: 29660006.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    59. Harrison RA, de Groot JF. Treatment of Glioblastoma in the Elderly. Drugs Aging. 2018 Aug; 35(8):707-718. PMID: 30039343.
      Citations: 5     Fields:    Translation:Humans
    60. Schomann T, Ramekers D, de Groot JCMJ, van der Ploeg CH, Hendriksen FGJ, Böhringer S, Klis SFL, Frijns JHM, Huisman MA. Ouabain Does Not Induce Selective Spiral Ganglion Cell Degeneration in Guinea Pigs. Biomed Res Int. 2018; 2018:1568414. PMID: 30151372.
      Citations: 2     Fields:    Translation:AnimalsCells
    61. Zinn PO, Singh SK, Kotrotsou A, Hassan I, Thomas G, Luedi MM, Elakkad A, Elshafeey N, Idris T, Mosley J, Gumin J, Fuller GN, de Groot JF, Baladandayuthapani V, Sulman EP, Kumar AJ, Sawaya R, Lang FF, Piwnica-Worms D, Colen RR. A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. Clin Cancer Res. 2018 12 15; 24(24):6288-6299. PMID: 30054278.
      Citations: 30     Fields:    Translation:HumansAnimals
    62. Mandel JJ, Youssef M, Ludmir E, Yust-Katz S, Patel AJ, De Groot JF. Highlighting the need for reliable clinical trials in glioblastoma. Expert Rev Anticancer Ther. 2018 10; 18(10):1031-1040. PMID: 29973092.
      Citations: 7     Fields:    Translation:Humans
    63. Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver N, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018 07; 24(7):1036-1046. PMID: 29892070.
      Citations: 165     Fields:    Translation:HumansAnimalsCells
    64. Ferguson SD, Zhou S, Huse JT, de Groot JF, Xiu J, Subramaniam DS, Mehta S, Gatalica Z, Swensen J, Sanai N, Spetzler D, Heimberger AB. Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. J Neuropathol Exp Neurol. 2018 06 01; 77(6):437-442. PMID: 29718398.
      Citations: 14     Fields:    Translation:HumansCells
    65. van der Horn HJ, de Haan S, Spikman JM, de Groot JC, van der Naalt J. Clinical relevance of microhemorrhagic lesions in subacute mild traumatic brain injury. Brain Imaging Behav. 2018 Jun; 12(3):912-916. PMID: 28664231.
      Citations: 12     Fields:    Translation:Humans
    66. Kotrotsou A, Elakkad A, Sun J, Thomas GA, Yang D, Abrol S, Wei W, Weinberg JS, Bakhtiari AS, Kircher MF, Luedi MM, de Groot JF, Sawaya R, Kumar AJ, Zinn PO, Colen RR. Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome. J Neurooncol. 2018 Aug; 139(1):125-133. PMID: 29619649.
      Citations: 5     Fields:    Translation:Humans
    67. Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):259-267. PMID: 29036345.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    68. Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):249-258. PMID: 29016998.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    69. Mandel JJ, Yust-Katz S, Patel AJ, Cachia D, Liu D, Park M, Yuan Y, Kent TA, de Groot JF. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 2018 01 10; 20(1):113-122. PMID: 29016865.
      Citations: 16     Fields:    Translation:Humans
    70. Dong J, Park SY, Nguyen N, Ezhilarasan R, Martinez-Ledesma E, Wu S, Henry V, Piao Y, Tiao N, Brunell D, Stephan C, Verhaak R, Sulman E, Balasubramaniyan V, de Groot JF. The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells. Oncotarget. 2018 Feb 13; 9(12):10497-10509. PMID: 29535822.
      Citations: 4     Fields:    
    71. Ferguson SD, Zhou S, Xiu J, Hashimoto Y, Sanai N, Kim L, Kesari S, de Groot J, Spetzler D, Heimberger AB. Ependymomas overexpress chemoresistance and DNA repair-related proteins. Oncotarget. 2018 Jan 30; 9(8):7822-7831. PMID: 29487694.
      Citations: 2     Fields:    
    72. Schomann T, Mezzanotte L, De Groot JCMJ, Rivolta MN, Hendriks SH, Frijns JHM, Huisman MA. Neuronal differentiation of hair-follicle-bulge-derived stem cells co-cultured with mouse cochlear modiolus explants. PLoS One. 2017; 12(10):e0187183. PMID: 29084289.
      Citations: 1     Fields:    Translation:AnimalsCells
    73. Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018 01 15; 24(2):295-305. PMID: 29074604.
      Citations: 19     Fields:    Translation:Humans
    74. Lee JH, Liu R, Li J, Zhang C, Wang Y, Cai Q, Qian X, Xia Y, Zheng Y, Piao Y, Chen Q, de Groot JF, Jiang T, Lu Z. Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis. Nat Commun. 2017 10 16; 8(1):949. PMID: 29038421.
      Citations: 53     Fields:    Translation:HumansCells
    75. Boonyawan K, Hess KR, Yang J, Long L, Wang Q, Ezhilarasan R, Auia A, Alfaro-Munoz KD, de Groot JF, Bhat KP, Sulman EP. A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma. Oncotarget. 2017 Oct 27; 8(52):90488-90495. PMID: 29163847.
      Citations: 4     Fields:    
    76. Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Brachman D, Jenrette JM, De Groot J, Bovi JA, Werner-Wasik M, Knisely JPS, Mehta MP. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2018 07; 129(1):35-47. PMID: 28984517.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    77. Nam JY, de Groot JF. Treatment of Glioblastoma. J Oncol Pract. 2017 10; 13(10):629-638. PMID: 29020535.
      Citations: 35     Fields:    Translation:HumansCells
    78. Penas-Prado M, de Groot J. CATNON interim results: another triumph of upfront chemotherapy in glioma. Neuro Oncol. 2017 10 01; 19(10):1287-1288. PMID: 28922864.
      Citations: 1     Fields:    Translation:Humans
    79. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan; 15(1):47-62. PMID: 28925994.
      Citations: 459     Fields:    Translation:Humans
    80. Daher A, de Groot J. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model. Exp Neurol. 2018 01; 299(Pt B):281-288. PMID: 28923369.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    81. de Haan S, de Groot JC, Jacobs B, van der Naalt J. The association between microhaemorrhages and post - traumatic functional outcome in the chronic phase after mild traumatic brain injury. Neuroradiology. 2017 Oct; 59(10):963-969. PMID: 28785801.
      Citations: 5     Fields:    Translation:Humans
    82. Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017 Aug 01; 19(8):1047-1057. PMID: 28371827.
      Citations: 124     Fields:    Translation:HumansCells
    83. Piao Y, Henry V, Tiao N, Park SY, Martinez-Ledesma J, Dong JW, Balasubramaniyan V, de Groot JF. Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma. Oncotarget. 2017 Nov 14; 8(57):96970-96983. PMID: 29228586.
      Citations: 10     Fields:    
    84. Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 01; 23(19):5745-5756. PMID: 28655794.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    85. Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367. PMID: 28148207.
      Citations: 20     Fields:    Translation:Humans
    86. Harrison RA, de Groot JF. Cell Signaling Pathways in Brain Tumors. Top Magn Reson Imaging. 2017 Feb; 26(1):15-26. PMID: 28079711.
      Citations:    Fields:    Translation:HumansCells
    87. Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 03; 132(1):181-188. PMID: 28116649.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    88. Schomann T, Mezzanotte L, Lourens IM, de Groot JC, Frijns JH, Huisman MA. Lentiviral transduction and subsequent loading with nanoparticles do not affect cell viability and proliferation in hair-follicle-bulge-derived stem cells in vitro. Contrast Media Mol Imaging. 2016 11; 11(6):550-560. PMID: 27976505.
      Citations: 4     Fields:    Translation:AnimalsCells
    89. Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2016 11; 29(6):627-642. PMID: 27615400.
      Citations: 31     Fields:    Translation:Humans
    90. O'Neill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016 12; 130(3):495-503. PMID: 27576699.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    91. Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol. 2016 09; 129(3):487-494. PMID: 27406589.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    92. Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66. PMID: 27370400.
      Citations: 58     Fields:    Translation:HumansCells
    93. Park SY, Piao Y, Jeong KJ, Dong J, de Groot JF. Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models. Mol Cancer Ther. 2016 09; 15(9):2187-97. PMID: 27307601.
      Citations: 32     Translation:HumansAnimalsCells
    94. Mandel JJ, Cachia D, Liu D, Wilson C, Aldape K, Fuller G, de Groot JF. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol. 2016 08; 129(1):147-54. PMID: 27270908.
      Citations: 12     Fields:    Translation:Humans
    95. Park SY, Piao Y, Thomas C, Fuller GN, de Groot JF. Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma. Oncotarget. 2016 May 03; 7(18):26793-805. PMID: 27050366.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    96. Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL, de Groot JF. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro Oncol. 2016 09; 18(9):1230-41. PMID: 26965451.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    97. Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Jun; 5(6):e1145332. PMID: 27471611.
      Citations: 10     
    98. Janmaat CJ, de Rooij KE, Locher H, de Groot SC, de Groot JC, Frijns JH, Huisman MA. Human Dermal Fibroblasts Demonstrate Positive Immunostaining for Neuron- and Glia- Specific Proteins. PLoS One. 2015; 10(12):e0145235. PMID: 26678612.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    99. Gatson NT, Weathers SP, de Groot JF. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma. CNS Oncol. 2016; 5(1):11-26. PMID: 26670466.
      Citations: 7     Fields:    
    100. Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol. 2016 Jan; 126(2):309-16. PMID: 26508094.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    101. Liang J, Piao Y, Henry V, Tiao N, de Groot JF. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy. Oncotarget. 2015 Oct 13; 6(31):31479-92. PMID: 26362401.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    102. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016 Apr; 18(4):557-64. PMID: 26449250.
      Citations: 165     Fields:    Translation:HumansCTClinical Trials
    103. Weathers SP, de Groot J. VEGF Manipulation in Glioblastoma. Oncology (Williston Park). 2015 Oct; 29(10):720-7. PMID: 26470893.
      Citations: 29     Fields:    Translation:Humans
    104. Webre C, Shonka N, Smith L, Liu D, De Groot J. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine. Anticancer Res. 2015 Oct; 35(10):5467-72. PMID: 26408710.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    105. Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS, Fuller GN, Gilbert MR, De Groot JF. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol. 2015 Nov; 125(2):401-10. PMID: 26354773.
      Citations: 17     Fields:    Translation:Humans
    106. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62. PMID: 26014291.
      Citations: 165     Fields:    Translation:Humans
    107. Postma IR, van Oosterhout WP, de Groot JC, Terwindt GM, Zeeman GG. The presence of brain white matter lesions in relation to preeclampsia and migraine. Cephalalgia. 2016 Mar; 36(3):284-8. PMID: 25957305.
      Citations:    Fields:    Translation:Humans
    108. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug; 17(8):1051-63. PMID: 25934816.
      Citations: 82     Fields:    Translation:Humans
    109. Theeler BJ, Ellezam B, Melguizo-Gavilanes I, de Groot JF, Mahajan A, Aldape KD, Bruner JM, Puduvalli VK. Adult brainstem gliomas: Correlation of clinical and molecular features. J Neurol Sci. 2015; 353(1-2):92-7. PMID: 25934342.
      Citations: 10     Fields:    Translation:Humans
    110. de Groot JF. High-grade gliomas. Continuum (Minneap Minn). 2015 Apr; 21(2 Neuro-oncology):332-44. PMID: 25837899.
      Citations: 17     Fields:    Translation:Humans
    111. Martinez-Ledesma E, de Groot JF, Verhaak RG. Seek and destroy: relating cancer drivers to therapies. Cancer Cell. 2015 Mar 09; 27(3):319-21. PMID: 25759016.
      Citations: 4     Fields:    Translation:Humans
    112. Locher H, Saadah N, de Groot S, de Groot JC, Frijns JH, Huisman MA. Hair follicle bulge cultures yield class III ß-tubulin-positive melanoglial cells. Histochem Cell Biol. 2015 Jul; 144(1):87-91. PMID: 25724811.
      Citations: 1     Fields:    Translation:AnimalsCells
    113. Locher H, de Groot JC, van Iperen L, Huisman MA, Frijns JH, Chuva de Sousa Lopes SM. Development of the stria vascularis and potassium regulation in the human fetal cochlea: Insights into hereditary sensorineural hearing loss. Dev Neurobiol. 2015 Nov; 75(11):1219-40. PMID: 25663387.
      Citations: 26     Fields:    Translation:HumansCells
    114. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem. 2015 Mar; 61(3):544-53. PMID: 25626406.
      Citations: 53     Fields:    Translation:Humans
    115. Mella DB, Kamiya-Matsuoka C, Liao B, Tummala S, de Groot J. Recurrent encephaloclastic cyst induced by intraventricular topotecan. J Neurol Sci. 2015 Feb 15; 349(1-2):52-3. PMID: 25598491.
      Citations: 1     Fields:    Translation:Humans
    116. Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. 2014 Nov 15; 20(22):5612-9. PMID: 25398844.
      Citations: 51     Fields:    Translation:Humans
    117. Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Invest New Drugs. 2015 Feb; 33(1):247-53. PMID: 25388940.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    118. Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015 Feb; 17(2):266-73. PMID: 25239666.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    119. Mandel JJ, Yust-Katz S, Cachia D, Wu J, Liu D, de Groot JF, Yung AW, Gilbert MR. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. J Neurooncol. 2014 Dec; 120(3):597-605. PMID: 25168214.
      Citations: 16     Fields:    Translation:Humans
    120. Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8. PMID: 25165194.
      Citations: 11     Fields:    Translation:Humans
    121. Theeler BJ, Ellezam B, Yust-Katz S, Slopis JM, Loghin ME, de Groot JF. Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab. J Neurol. 2014 Aug; 261(8):1559-64. PMID: 24859329.
      Citations: 8     Fields:    Translation:Humans
    122. Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, DeGroot JF. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol. 2014 Aug; 119(1):135-40. PMID: 24803001.
      Citations: 15     Fields:    Translation:Humans
    123. Weathers SP, de Groot J. Resistance to antiangiogenic therapy. Curr Neurol Neurosci Rep. 2014 May; 14(5):443. PMID: 24652451.
      Citations: 5     Fields:    Translation:HumansAnimals
    124. de Groot JF, Mandel JJ. Update on anti-angiogenic treatment for malignant gliomas. Curr Oncol Rep. 2014 Apr; 16(4):380. PMID: 24510742.
      Citations: 8     Fields:    Translation:Humans
    125. Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One. 2014; 9(3):e91216. PMID: 24614622.
      Citations: 38     Fields:    Translation:HumansCells
    126. Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS. Pregnancy and glial brain tumors. Neuro Oncol. 2014 Sep; 16(9):1289-94. PMID: 24615863.
      Citations: 17     Fields:    Translation:Humans
    127. Locher H, de Groot JC, van Iperen L, Huisman MA, Frijns JH, Chuva de Sousa Lopes SM. Distribution and development of peripheral glial cells in the human fetal cochlea. PLoS One. 2014; 9(1):e88066. PMID: 24498246.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    128. Yust-Katz S, Anderson MD, Liu D, Wu J, Yuan Y, Olar A, Fuller GN, Brown PD, de-Groot JF. Clinical and prognostic features of adult patients with gangliogliomas. Neuro Oncol. 2014 Mar; 16(3):409-13. PMID: 24305706.
      Citations: 12     Fields:    Translation:Humans
    129. Barney CL, Brown AP, Grosshans DR, McAleer MF, de Groot JF, Puduvalli V, Tucker SL, Crawford CN, Gilbert MR, Brown PD, Mahajan A. Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation. Neuro Oncol. 2014 Jan; 16(2):303-9. PMID: 24311638.
      Citations: 7     Fields:    Translation:Humans
    130. Kamiya-Matsuoka C, Garciarena P, Amin HM, Tremont-Lukats IW, de Groot JF. B lymphoblastic leukemia/lymphoma presenting as seventh cranial nerve palsy. Neurol Clin Pract. 2013 Dec; 3(6):532-534. PMID: 30107017.
    131. Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, de Groot JF. Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res. 2014 Jan 01; 20(1):187-98. PMID: 24240114.
      Citations: 86     Fields:    Translation:HumansAnimalsCells
    132. Locher H, Frijns JH, van Iperen L, de Groot JC, Huisman MA, Chuva de Sousa Lopes SM. Neurosensory development and cell fate determination in the human cochlea. Neural Dev. 2013 Oct 16; 8:20. PMID: 24131517.
      Citations: 18     Fields:    Translation:HumansCells
    133. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013 Sep 10; 31(26):3212-8. PMID: 23940216.
      Citations: 202     Fields:    Translation:HumansCTClinical Trials
    134. Locher H, de Rooij KE, de Groot JC, van Doorn R, Gruis NA, Löwik CW, Chuva de Sousa Lopes SM, Frijns JH, Huisman MA. Class III ß-tubulin, a novel biomarker in the human melanocyte lineage. Differentiation. 2013 Apr-Jun; 85(4-5):173-81. PMID: 23817083.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    135. Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 2013 Aug 15; 19(16):4392-403. PMID: 23804423.
      Citations: 80     Fields:    Translation:HumansAnimalsCells
    136. Chen SE, Choi SS, Rogers JE, Lei X, De Groot JF. Isotretinoin maintenance therapy for glioblastoma: a retrospective review. J Oncol Pharm Pract. 2014 Apr; 20(2):112-9. PMID: 23676507.
      Citations: 1     Fields:    Translation:Humans
    137. Stronks HC, Versnel H, Prijs VF, de Groot JC, Grolman W, Klis SF. The role of electrophonics in electroacoustic stimulation of the guinea pig cochlea. Otol Neurotol. 2013 Apr; 34(3):579-87. PMID: 23449442.
      Citations: 2     Fields:    Translation:AnimalsCells
    138. Brown AP, Barney CL, Grosshans DR, McAleer MF, de Groot JF, Puduvalli VK, Tucker SL, Crawford CN, Khan M, Khatua S, Gilbert MR, Brown PD, Mahajan A. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys. 2013 Jun 01; 86(2):277-84. PMID: 23433794.
      Citations: 37     Fields:    Translation:Humans
    139. van Loon MC, Ramekers D, Agterberg MJ, de Groot JC, Grolman W, Klis SF, Versnel H. Spiral ganglion cell morphology in guinea pigs after deafening and neurotrophic treatment. Hear Res. 2013 Apr; 298:17-26. PMID: 23361189.
      Citations: 13     Fields:    Translation:AnimalsCells
    140. Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol. 2013 Jun; 8(2):117-25. PMID: 23345034.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    141. de Groot J, Reardon DA, Batchelor TT. Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714460.
      Citations: 5     Fields:    Translation:HumansCells
    142. de Groot JF. Prediction of response to chemotherapy in anaplastic glioma: how many markers does it take? J Clin Oncol. 2013 Jan 20; 31(3):297-8. PMID: 23269985.
      Citations: 2     Fields:    Translation:Humans
    143. Wang M, Dignam JJ, Zhang QE, DeGroot JF, Mehta MP, Hunsberger S. Integrated phase II/III clinical trials in oncology: a case study. Clin Trials. 2012 Dec; 9(6):741-7. PMID: 23180870.
      Citations: 2     Fields:    Translation:Humans
    144. Shonka N, Brandes A, De Groot JF. Adult medulloblastoma, from spongioblastoma cerebelli to the present day: a review of treatment and the integration of molecular markers. Oncology (Williston Park). 2012 Nov; 26(11):1083-91. PMID: 23330353.
      Citations:    Fields:    Translation:Humans
    145. Theeler BJ, Yung WK, Fuller GN, De Groot JF. Moving toward molecular classification of diffuse gliomas in adults. Neurology. 2012 Oct 30; 79(18):1917-26. PMID: 23109653.
      Citations: 29     Fields:    Translation:Humans
    146. Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, de Groot JF. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol. 2012 Nov; 14(11):1379-92. PMID: 22965162.
      Citations: 98     Fields:    Translation:HumansAnimalsCells
    147. de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W, Heimberger AB. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget. 2012 Sep; 3(9):1036-48. PMID: 23013619.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    148. Grossmann KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, De Groot JF, Aiken RD, Olson JJ, Olsen JJ, Evans BA, Jensen RL. Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. J Neurooncol. 2012 Nov; 110(2):257-64. PMID: 22932984.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    149. Aukes AM, De Groot JC, Wiegman MJ, Aarnoudse JG, Sanwikarja GS, Zeeman GG. Long-term cerebral imaging after pre-eclampsia. BJOG. 2012 Aug; 119(9):1117-22. PMID: 22703533.
      Citations: 25     Fields:    Translation:Humans
    150. Wiegman MJ, Zeeman GG, Aukes AM, Faas MM, Aarnoudse JG, de Groot JC. OS072. Regional distribution of cerebral white matter lesions years following (pre)eclampsia. Pregnancy Hypertens. 2012 Jul; 2(3):216-7. PMID: 26105286.
      Citations:    Fields:    
    151. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronjé MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, Díaz-Araya G, Díaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farré JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, Fésüs L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544. PMID: 22966490.
      Citations: 1636     Fields:    Translation:HumansAnimals
    152. Walker GV, Li J, Mahajan A, McAleer MF, de Groot JF, Azeem SS, Brown PD. Decreasing radiation therapy utilization in adult patients with glioblastoma multiforme: a population-based analysis. Cancer. 2012 Sep 15; 118(18):4538-44. PMID: 22359097.
      Citations: 5     Fields:    Translation:Humans
    153. Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 2012 Jul 15; 118(14):3599-606. PMID: 22086614.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    154. de Groot JF. High-dose antiangiogenic therapy for glioblastoma: less may be more? Clin Cancer Res. 2011 Oct 01; 17(19):6109-11. PMID: 21852387.
      Citations: 12     Fields:    Translation:HumansAnimals
    155. Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3. PMID: 21768451.
      Citations: 9     Fields:    Translation:Humans
    156. de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res. 2011 Jul 15; 17(14):4872-81. PMID: 21632852.
      Citations: 27     Fields:    Translation:HumansCellsCTClinical Trials
    157. Bremer HG, de Groot JC, Versnel H, Klis SF. Combined administration of kanamycin and furosemide does not result in loss of vestibular function in Guinea pigs. Audiol Neurootol. 2012; 17(1):25-38. PMID: 21625081.
      Citations: 4     Fields:    Translation:AnimalsCells
    158. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011 Jul 01; 29(19):2689-95. PMID: 21606416.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    159. de Groot JF, Sulman EP, Aldape KD. Multigene sets for clinical application in glioma. J Natl Compr Canc Netw. 2011 Apr; 9(4):449-56; quiz 457. PMID: 21464148.
      Citations: 1     Fields:    Translation:HumansCells
    160. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61. PMID: 21310734.
      Citations: 50     Fields:    Translation:Humans
    161. de Groot J, Sontheimer H. Glutamate and the biology of gliomas. Glia. 2011 Aug; 59(8):1181-9. PMID: 21192095.
      Citations: 102     Fields:    Translation:HumansAnimalsCells
    162. Ahluwalia MS, de Groot J, Liu WM, Gladson CL. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett. 2010 Dec 08; 298(2):139-49. PMID: 20947248.
      Citations: 58     Fields:    Translation:HumansCells
    163. Mostert JP, Koch MW, Steen C, Heersema DJ, De Groot JC, De Keyser J. T2 lesions and rate of progression of disability in multiple sclerosis. Eur J Neurol. 2010 Dec; 17(12):1471-5. PMID: 20500805.
      Citations: 9     Fields:    Translation:Humans
    164. Havenith S, Versnel H, Agterberg MJ, de Groot JC, Sedee RJ, Grolman W, Klis SF. Spiral ganglion cell survival after round window membrane application of brain-derived neurotrophic factor using gelfoam as carrier. Hear Res. 2011 Feb; 272(1-2):168-77. PMID: 20969940.
      Citations: 17     Fields:    Translation:Animals
    165. Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WK. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol. 2010 Nov; 12(11):1167-72. PMID: 20729242.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    166. Timmerman H, de Groot JF, Hulzebos HJ, de Knikker R, Kerkkamp HE, van Meeteren NL. Feasibility and preliminary effectiveness of preoperative therapeutic exercise in patients with cancer: a pragmatic study. Physiother Theory Pract. 2011 Feb; 27(2):117-24. PMID: 20690877.
      Citations: 12     Fields:    Translation:Humans
    167. Agterberg MJ, Versnel H, de Groot JC, van den Broek M, Klis SF. Chronic electrical stimulation does not prevent spiral ganglion cell degeneration in deafened guinea pigs. Hear Res. 2010 Oct 01; 269(1-2):169-79. PMID: 20600740.
      Citations: 10     Fields:    Translation:AnimalsCells
    168. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72. PMID: 20231676.
      Citations: 1298     Fields:    Translation:Humans
    169. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010 Mar; 12(3):233-42. PMID: 20167811.
      Citations: 234     Fields:    Translation:HumansAnimals
    170. Sijens PE, Westerlaan HE, de Groot JC, Boon M, Potze JH, van Spronsen FJ, Lunsing RJ, Oudkerk M. MR spectroscopy and diffusion tensor imaging of the brain in Sjögren-Larsson syndrome. Mol Genet Metab. 2009 Dec; 98(4):367-71. PMID: 19656702.
      Citations: 2     Fields:    Translation:Humans
    171. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res. 2009 Jul 15; 15(14):4589-99. PMID: 19567589.
      Citations: 98     Fields:    Translation:HumansAnimalsCells
    172. de Groot J, Milano V. Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. J Neurooncol. 2009 Nov; 95(2):151-163. PMID: 19436954.
      Citations: 21     Fields:    Translation:Humans
    173. Ter Haar G, de Groot JC, Venker-van Haagen AJ, van Sluijs FJ, Smoorenburg GF. Effects of aging on inner ear morphology in dogs in relation to brainstem responses to toneburst auditory stimuli. J Vet Intern Med. 2009 May-Jun; 23(3):536-43. PMID: 19645839.
      Citations: 2     Fields:    Translation:Animals
    174. Agterberg MJ, Versnel H, van Dijk LM, de Groot JC, Klis SF. Enhanced survival of spiral ganglion cells after cessation of treatment with brain-derived neurotrophic factor in deafened guinea pigs. J Assoc Res Otolaryngol. 2009 Sep; 10(3):355-67. PMID: 19365690.
      Citations: 42     Fields:    Translation:Animals
    175. Vaillant B, Kuo SH, de Groot J. Emerging subspecialties in neurology: neuro-oncology: a developing subspecialty with many opportunities. Neurology. 2009 Mar 17; 72(11):e51-3. PMID: 19289732.
      Citations: 1     Fields:    Translation:Humans
    176. Walker JG, Kadia T, Brown L, Juneja HS, de Groot JF. Dapsone induced methemoglobinemia in a patient with glioblastoma. J Neurooncol. 2009 Aug; 94(1):149-52. PMID: 19219404.
      Citations: 4     Fields:    Translation:Humans
    177. Milano V, Piao Y, LaFortune T, de Groot J. Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther. 2009 Feb; 8(2):394-406. PMID: 19190119.
      Citations: 59     Translation:HumansCells
    178. Kuo SH, Debnam JM, Fuller GN, de Groot J. Wernicke's encephalopathy: an underrecognized and reversible cause of confusional state in cancer patients. Oncology. 2009; 76(1):10-8. PMID: 19018150.
      Citations: 18     Fields:    Translation:Humans
    179. Gonzalez J, de Groot J. Combination therapy for malignant glioma based on PTEN status. Expert Rev Anticancer Ther. 2008 Nov; 8(11):1767-79. PMID: 18983237.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    180. Piao Y, Lu L, de Groot J. AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol. 2009 Jun; 11(3):260-73. PMID: 18957620.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    181. de Groot JF, Yung WK. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J. 2008 Sep-Oct; 14(5):279-85. PMID: 18836331.
      Citations: 21     Fields:    Translation:Humans
    182. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol. 2008 Dec; 10(6):940-5. PMID: 18708344.
      Citations: 42     Fields:    Translation:HumansAnimals
    183. Agterberg MJ, Versnel H, de Groot JC, Smoorenburg GF, Albers FW, Klis SF. Morphological changes in spiral ganglion cells after intracochlear application of brain-derived neurotrophic factor in deafened guinea pigs. Hear Res. 2008 Oct; 244(1-2):25-34. PMID: 18692557.
      Citations: 35     Fields:    Translation:AnimalsCells
    184. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol. 2008 Oct; 90(1):89-97. PMID: 18581057.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    185. de Groot JF, Piao Y, Lu L, Fuller GN, Yung WK. Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol. 2008 Jun; 88(2):121-33. PMID: 18317690.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    186. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008 Apr; 10(2):216-22. PMID: 18314417.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    187. de Groot JF, Gilbert MR. New molecular targets in malignant gliomas. Curr Opin Neurol. 2007 Dec; 20(6):712-8. PMID: 17992095.
      Citations: 17     Fields:    Translation:Humans
    188. Mostert JP, de Groot JC, Ramsaransing GS, Koch MW, De Keyser J. Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis. Eur J Neurol. 2007 Nov; 14(11):1210-5. PMID: 17956444.
      Citations:    Fields:    Translation:Humans
    189. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, Jackson D, de Groot J, Yung WK. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther. 2007 Apr; 6(4):1357-67. PMID: 17431114.
      Citations: 77     Translation:AnimalsCells
    190. Versnel H, Agterberg MJ, de Groot JC, Smoorenburg GF, Klis SF. Time course of cochlear electrophysiology and morphology after combined administration of kanamycin and furosemide. Hear Res. 2007 Sep; 231(1-2):1-12. PMID: 17475424.
      Citations: 27     Fields:    Translation:AnimalsCells
    191. Koul D, Shen R, Bergh S, Sheng X, Shishodia S, Lafortune TA, Lu Y, de Groot JF, Mills GB, Yung WK. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther. 2006 Mar; 5(3):637-44. PMID: 16546978.
      Citations: 36     Translation:HumansCells
    192. Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ, Mills GB, Yung WK. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther. 2005 Nov; 4(11):1681-8. PMID: 16275989.
      Citations: 31     Translation:HumansCells
    193. de Groot JC, Hendriksen EG, Smoorenburg GF. Reduced expression of sialoglycoconjugates in the outer hair cell glycocalyx after systemic aminoglycoside administration. Hear Res. 2005 Jul; 205(1-2):68-82. PMID: 15953516.
      Citations: 2     Fields:    Translation:AnimalsCellsCTClinical Trials
    194. van Ruijven MW, de Groot JC, Klis SF, Smoorenburg GF. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res. 2005 Jul; 205(1-2):241-8. PMID: 15953532.
      Citations: 37     Fields:    Translation:Animals
    195. van Ruijven MW, de Groot JC, Hendriksen F, Smoorenburg GF. Immunohistochemical detection of platinated DNA in the cochlea of cisplatin-treated guinea pigs. Hear Res. 2005 May; 203(1-2):112-21. PMID: 15855036.
      Citations: 19     Fields:    Translation:AnimalsCells
    196. de Groot JF, Liu TJ, Fuller G, Yung WK. The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res. 2005 Mar 01; 65(5):1934-40. PMID: 15753393.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    197. van Ruijven MW, de Groot JC, Smoorenburg GF. Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration. A quantitative histological study. Hear Res. 2004 Nov; 197(1-2):44-54. PMID: 15504603.
      Citations: 22     Fields:    Translation:Animals
    198. van Dijk EJ, Vermeer SE, de Groot JC, van de Minkelis J, Prins ND, Oudkerk M, Hofman A, Koudstaal PJ, Breteler MM. Arterial oxygen saturation, COPD, and cerebral small vessel disease. J Neurol Neurosurg Psychiatry. 2004 May; 75(5):733-6. PMID: 15090569.
      Citations: 21     Fields:    Translation:Humans
    199. Cardinaal RM, De Groot JC, Huizing EH, Smoorenburg GF, Veldman JE. Ultrastructural changes in the albino guinea pig cochlea at different survival times following cessation of 8-day cisplatin administration. Acta Otolaryngol. 2004 Mar; 124(2):144-54. PMID: 15072416.
      Citations: 8     Fields:    Translation:AnimalsCells
    200. Wolters FL, Klis SF, Hamers FP, de Groot JC, Smoorenburg GF. Perilymphatic application of alpha-melanocyte stimulating hormone ameliorates hearing loss caused by systemic administration of cisplatin. Hear Res. 2004 Mar; 189(1-2):31-40. PMID: 14987750.
      Citations: 2     Fields:    Translation:AnimalsCells
    201. Benjamin RK, Hochberg FH, Fox E, Bungay PM, Elmquist WF, Stewart CF, Gallo JM, Collins JM, Pelletier RP, de Groot JF, Hickner RC, Cavus I, Grossman SA, Colvin OM. Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium. Neuro Oncol. 2004 Jan; 6(1):65-74. PMID: 14769143.
      Citations: 12     Fields:    Translation:HumansAnimals
    202. Sluyter S, Klis SF, de Groot JC, Smoorenburg GF. Alterations in the stria vascularis in relation to cisplatin ototoxicity and recovery. Hear Res. 2003 Nov; 185(1-2):49-56. PMID: 14599692.
      Citations: 12     Fields:    Translation:Animals
    203. Wolters FL, Klis SF, de Groot JC, Hamers FP, Prieskorn DM, Miller JM, Smoorenburg GF. Systemic co-treatment with alpha-melanocyte stimulating hormone delays hearing loss caused by local cisplatin administration in guinea pigs. Hear Res. 2003 May; 179(1-2):53-61. PMID: 12742238.
      Citations: 3     Fields:    Translation:AnimalsCells
    204. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, Breteler MM. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain. 2002 Apr; 125(Pt 4):765-72. PMID: 11912110.
      Citations: 161     Fields:    Translation:HumansCells
    205. Klis SF, O'Leary SJ, Wijbenga J, de Groot JC, Hamers FP, Smoorenburg GF. Partial recovery of cisplatin-induced hearing loss in the albino guinea pig in relation to cisplatin dose. Hear Res. 2002 Feb; 164(1-2):138-46. PMID: 11950533.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    206. de Leeuw FE, de Groot JC, van Gijn J. [Cerebral white matter lesions in the elderly: vascular risk factors and cognitive consequences]. Ned Tijdschr Geneeskd. 2001 Oct 27; 145(43):2067-71. PMID: 11715591.
      Citations: 2     Fields:    Translation:Humans
    207. Sijens PE, Den Heijer T, De Leeuw FE, De Groot JC, Achten E, Heijboer RJ, Hofman A, Breteler MM, Oudkerk M. Human brain chemical shift imaging at age 60 to 90: analysis of the causes of the observed sex differences in brain metabolites. Invest Radiol. 2001 Oct; 36(10):597-603. PMID: 11577270.
      Citations:    Fields:    Translation:Humans
    208. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM. Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam Scan Study. Neurology. 2001 Jun 12; 56(11):1539-45. PMID: 11402112.
      Citations: 89     Fields:    Translation:HumansCells
    209. den Heijer T, Launer LJ, de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Breteler MM. Serum carotenoids and cerebral white matter lesions: the Rotterdam scan study. J Am Geriatr Soc. 2001 May; 49(5):642-6. PMID: 11380759.
      Citations: 8     Fields:    Translation:Humans
    210. O'Leary SJ, Klis SF, de Groot JC, Hamers FP, Smoorenburg GF. Perilymphatic application of cisplatin over several days in albino guinea pigs: dose-dependency of electrophysiological and morphological effects. Hear Res. 2001 Apr; 154(1-2):135-45. PMID: 11423224.
      Citations: 3     Fields:    Translation:AnimalsCells
    211. Lankhorst AJ, ter Laak MP, van Laar TJ, van Meeteren NL, de Groot JC, Schrama LH, Hamers FP, Gispen WH. Effects of enriched housing on functional recovery after spinal cord contusive injury in the adult rat. J Neurotrauma. 2001 Feb; 18(2):203-15. PMID: 11229712.
      Citations: 28     Fields:    Translation:AnimalsCells
    212. de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, Hofman A, Jolles J, van Gijn J, Breteler MM. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry. 2001 Jan; 70(1):9-14. PMID: 11118240.
      Citations: 324     Fields:    Translation:Humans
    213. Sijens PE, den Heijer T, de Leeuw FE, de Groot JC, Achten E, Heijboer RJ, Hofman A, Breteler MM, Oudkerk M. MR spectroscopy detection of lactate and lipid signals in the brains of healthy elderly people. Eur Radiol. 2001; 11(8):1495-501. PMID: 11519564.
      Citations: 6     Fields:    Translation:Humans
    214. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM. Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry. 2000 Nov; 57(11):1071-6. PMID: 11074873.
      Citations: 87     Fields:    Translation:Humans
    215. Cardinaal RM, de Groot JC, Huizing EH, Veldman JE, Smoorenburg GF. Cisplatin-induced ototoxicity: morphological evidence of spontaneous outer hair cell recovery in albino guinea pigs? Hear Res. 2000 Jun; 144(1-2):147-56. PMID: 10831873.
      Citations: 12     Fields:    Translation:AnimalsCells
    216. Cardinaal RM, de Groot JC, Huizing EH, Veldman JE, Smoorenburg GF. Histological effects of co-administration of an ACTH((4-9)) analogue, ORG 2766, on cisplatin ototoxicity in the albino guinea pig. Hear Res. 2000 Jun; 144(1-2):157-67. PMID: 10831874.
      Citations: 5     Fields:    Translation:AnimalsCells
    217. Cardinaal RM, de Groot JC, Huizing EH, Veldman JE, Smoorenburg GF. Dose-dependent effect of 8-day cisplatin administration upon the morphology of the albino guinea pig cochlea. Hear Res. 2000 Jun; 144(1-2):135-46. PMID: 10831872.
      Citations: 13     Fields:    Translation:AnimalsCells
    218. de Leeuw FE, de Groot JC, Oudkerk M, Kors JA, Hofman A, van Gijn J, Breteler MM. Atrial fibrillation and the risk of cerebral white matter lesions. Neurology. 2000 May 09; 54(9):1795-801. PMID: 10802786.
      Citations: 28     Fields:    Translation:Humans
    219. Bouman H, Klis SF, Meeuwsen F, de Groot JC, Smoorenburg GF, Veldman JE. Experimental autoimmune inner ear disease: an electrocochleographic and histophysiologic study. Ann Otol Rhinol Laryngol. 2000 May; 109(5):457-66. PMID: 10823474.
      Citations: 2     Fields:    Translation:AnimalsPHPublic Health
    220. de Leeuw FE, de Groot JC, Bots ML, Witteman JC, Oudkerk M, Hofman A, van Gijn J, Breteler MM. Carotid atherosclerosis and cerebral white matter lesions in a population based magnetic resonance imaging study. J Neurol. 2000 Apr; 247(4):291-6. PMID: 10836622.
      Citations: 45     Fields:    Translation:Humans
    221. deGroot J, Zhou S, Carlton SM. Peripheral glutamate release in the hindpaw following low and high intensity sciatic stimulation. Neuroreport. 2000 Feb 28; 11(3):497-502. PMID: 10718302.
      Citations: 47     Fields:    Translation:AnimalsCells
    222. Klis SF, O'Leary SJ, Hamers FP, De Groot JC, Smoorenburg GF. Reversible cisplatin ototoxicity in the albino guinea pig. Neuroreport. 2000 Feb 28; 11(3):623-6. PMID: 10718325.
      Citations: 6     Fields:    Translation:Animals
    223. de Leeuw FE, De Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, Breteler MM. Aortic atherosclerosis at middle age predicts cerebral white matter lesions in the elderly. Stroke. 2000 Feb; 31(2):425-9. PMID: 10657417.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    224. de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J, Breteler MM. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol. 2000 Feb; 47(2):145-51. PMID: 10665484.
      Citations: 227     Fields:    Translation:Humans
    225. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, Breteler MM. A follow-up study of blood pressure and cerebral white matter lesions. Ann Neurol. 1999 Dec; 46(6):827-33. PMID: 10589534.
      Citations: 46     Fields:    Translation:Humans
    226. Smoorenburg GF, De Groot JC, Hamers FP, Klis SF. Protection and spontaneous recovery from cisplatin-induced hearing loss. Ann N Y Acad Sci. 1999 Nov 28; 884:192-210. PMID: 10842594.
      Citations: 4     Fields:    Translation:AnimalsCells
    227. Cappaert NL, Klis SF, Muijser H, de Groot JC, Kulig BM, Smoorenburg GF. The ototoxic effects of ethyl benzene in rats. Hear Res. 1999 Nov; 137(1-2):91-102. PMID: 10545637.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    228. Sijens PE, Oudkerk M, de Leeuw FE, de Groot JC, Achten E, Heijboer R, Hofman A, Breteler MM. 1H chemical shift imaging of the human brain at age 60-90 years reveals metabolic differences between women and men. Magn Reson Med. 1999 Jul; 42(1):24-31. PMID: 10398946.
      Citations: 2     Fields:    Translation:Humans
    229. Bakker SL, de Leeuw FE, de Groot JC, Hofman A, Koudstaal PJ, Breteler MM. Cerebral vasomotor reactivity and cerebral white matter lesions in the elderly. Neurology. 1999 Feb; 52(3):578-83. PMID: 10025791.
      Citations: 54     Fields:    Translation:Humans
    230. Heijmen PS, Klis SF, De Groot JC, Smoorenburg GF. Cisplatin ototoxicity and the possibly protective effect of alpha-melanocyte stimulating hormone. Hear Res. 1999 Feb; 128(1-2):27-39. PMID: 10082280.
      Citations: 1     Fields:    Translation:AnimalsCells
    231. Krabbe-Hartkamp MJ, van der Grond J, de Leeuw FE, de Groot JC, Algra A, Hillen B, Breteler MM, Mali WP. Circle of Willis: morphologic variation on three-dimensional time-of-flight MR angiograms. Radiology. 1998 Apr; 207(1):103-11. PMID: 9530305.
      Citations: 87     Fields:    Translation:Humans
    232. Bouman H, Klis SF, de Groot JC, Huizing EH, Smoorenburg GF, Veldman JE. Induction of endolymphatic hydrops in the guinea pig by perisaccular deposition of sepharose beads carrying and not carrying immune complexes. Hear Res. 1998 Mar; 117(1-2):119-30. PMID: 9557983.
      Citations: 2     Fields:    Translation:Animals
    233. de Groot JC, de Leeuw FE, Breteler MM. Cognitive correlates of cerebral white matter changes. J Neural Transm Suppl. 1998; 53:41-67. PMID: 9700645.
      Citations: 10     Fields:    Translation:HumansAnimals
    234. deGroot JF, Coggeshall RE, Carlton SM. The reorganization of mu opioid receptors in the rat dorsal horn following peripheral axotomy. Neurosci Lett. 1997 Sep 19; 233(2-3):113-6. PMID: 9350845.
      Citations: 7     Fields:    Translation:Animals
    235. de Groot JC, Hamers FP, Gispen WH, Smoorenburg GF. Co-administration of the neurotrophic ACTH(4-9) analogue, ORG 2766, may reduce the cochleotoxic effects of cisplatin. Hear Res. 1997 Apr; 106(1-2):9-19. PMID: 9112103.
      Citations: 1     Fields:    Translation:AnimalsCells
    236. Tagagi I, Hendriksen F, De Groot JC, Veldman JE. Demonstration of intermediate filament proteins in the guinea pig vestibular labyrinth by a new, high-resolution cryotechnique. Acta Otolaryngol Suppl. 1995; 520 Pt 2:377-80. PMID: 8749166.
      Citations:    Fields:    Translation:Animals
    237. van Benthem PP, de Groot JC, Albers FW, Veldman JE, Huizing EH. Structure and composition of stereocilia cross-links in normal and hydropic cochleas of the guinea pig. Eur Arch Otorhinolaryngol. 1993; 250(2):73-7. PMID: 8507469.
      Citations: 2     Fields:    Translation:AnimalsCells
    238. Van Benthem PP, Albers FW, De Groot JC, Veldman JE, Huizing EH. Glycocalyx heterogeneity in normal and hydropic cochleas of the guinea pig. Acta Otolaryngol. 1992 Nov; 112(6):976-84. PMID: 1481668.
      Citations:    Fields:    Translation:AnimalsCells
    239. Bauwens LJ, De Groot JC, Ramaekers FC, Veldman JE, Huizing EH. Expression of intermediate filament proteins in the adult human vestibular labyrinth. Ann Otol Rhinol Laryngol. 1992 Jun; 101(6):479-86. PMID: 1376975.
      Citations: 1     Fields:    Translation:Humans
    240. van Benthem PP, Albers FW, de Groot JC, Veldman JE, Huizing EH. Cell membrane polarity of the epithelial cells in the endolymphatic sac of the guinea pig. ORL J Otorhinolaryngol Relat Spec. 1992; 54(5):241-5. PMID: 1488245.
      Citations:    Fields:    Translation:AnimalsCells
    241. Bauwens LJ, De Groot JC, Ramaekers FC, Linthicum F, Veldman JE, Huizing EH. Differential immunohistochemical detection of cytokeratins and vimentin in the surgically removed human endolymphatic duct and sac. Eur Arch Otorhinolaryngol. 1991; 248(8):495-501. PMID: 1722680.
      Citations: 1     Fields:    Translation:Humans
    242. De Groot JC, Huizing EH, Veldman JE. Early ultrastructural effects of gentamicin cochleotoxicity. Acta Otolaryngol. 1991; 111(2):273-80. PMID: 2068914.
      Citations: 3     Fields:    Translation:AnimalsCells
    243. de Groot JC, Meeuwsen F, Ruizendaal WE, Veldman JE. Ultrastructural localization of gentamicin in the cochlea. Hear Res. 1990 Dec; 50(1-2):35-42. PMID: 2076981.
      Citations: 17     Fields:    Translation:AnimalsCells
    244. Veldman JE, Albers FM, Ruding PR, de Groot JC, Huizing EH. Functional ultrastructure of the inner ear in experimental hydrops. Adv Otorhinolaryngol. 1990; 45:154-74. PMID: 2077888.
      Citations:    Fields:    Translation:Animals
    245. de Groot JC, Veldman JE. Early effects of gentamicin on inner ear glycocalyx cytochemistry. Hear Res. 1988 Sep 01; 35(1):39-45. PMID: 3182408.
      Citations: 3     Fields:    Translation:AnimalsCells
    246. Albers FW, De Groot JC, Veldman JE, Huizing EH. Ultrastructure of the organ of Corti in experimental hydrops. Acta Otolaryngol. 1988 Mar-Apr; 105(3-4):281-91. PMID: 3389114.
      Citations: 4     Fields:    Translation:Animals
    247. Albers FW, de Groot JC, Veldman JE, Huizing EH. Ultrastructure of the stria vascularis and Reissner's membrane in experimental hydrops. Acta Otolaryngol. 1987 Sep-Oct; 104(3-4):202-10. PMID: 3673550.
      Citations: 1     Fields:    Translation:Animals
    248. de Groot JC, Veldman JE, Huizing EH. An improved fixation method for guinea pig cochlear tissues. Acta Otolaryngol. 1987 Sep-Oct; 104(3-4):234-42. PMID: 3118631.
      Citations: 6     Fields:    Translation:Animals
    249. Huizing EH, de Groot JC. Human cochlear pathology in aminoglycoside ototoxicity--a review. Acta Otolaryngol Suppl. 1987; 436:117-25. PMID: 3314323.
      Citations: 13     Fields:    Translation:Humans
    250. Albers FW, de Groot JC, Veldman JE, Huizing EH. Effects of endolymphatic sac obliteration on the cochlear duct glycocalyx. ORL J Otorhinolaryngol Relat Spec. 1987; 49(6):277-81. PMID: 3431837.
      Citations: 2     Fields:    Translation:AnimalsCells
    251. Backus RM, De Groot JC, Tange RA, Huizing EH. Pathological findings in the human auditory system following long-standing gentamicin ototoxicity. Arch Otorhinolaryngol. 1987; 244(2):69-73. PMID: 3662925.
      Citations: 2     Fields:    Translation:Humans
    252. Burgersdijk FJ, De Groot JC, Graamans K, Rademakers LH. Testing ciliary activity in patients with chronic and recurrent infections of the upper airways: experiences in 68 cases. Laryngoscope. 1986 Sep; 96(9 Pt 1):1029-33. PMID: 3528726.
      Citations: 1     Fields:    Translation:HumansCells
    253. Veldman JE, Visser CE, Schuurman HJ, de Groot JC, Huizing EH. Immunobiology of Langerhans' cells migrating into aural cholesteatomas. Otolaryngol Head Neck Surg. 1984 Feb; 92(1):1-6. PMID: 6422403.
      Citations: 2     Fields:    Translation:HumansCells
    254. B lymphoblastic leukemia/lymphoma presenting as seventh cranial nerve palsy. Neurology: Clinical Practice. 3:532-534.
    255. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. Journal of Neuro-Oncology. 1-8.
    256. Reply to J.W. Locasale et al. Journal of Clinical Oncology. 30:338-339.
    257. Periostin (POSTN) regulates tumor resistance to antiangiogenic therapy in glioma models. Molecular Cancer Therapeutics. 15:2187-2197.
    258. Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology.
    259. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy. Oncotarget. 6:31479-31492.
    260. Cell Signaling Pathways in Brain Tumors. Topics in Magnetic Resonance Imaging.
    261. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro-Oncology. 18:1230-1241.
    262. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma. Neuro-Oncology. 18:557-564.
    263. VEGF manipulation in glioblastoma. ONCOLOGY (United States). 29:720-727.
    264. Personalized medicine and targeted therapy of gliomas. 878-899.
    265. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. Journal of Neuro-Oncology.
    266. Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma. Oncotarget. 7:26793-26805.
    267. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. Journal of Clinical Oncology. 33:2753-2762.
    268. Effect of vascularization on glioma tumor growth. 237-259.
    269. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. Journal of Neuro-Oncology. 1-9.
    270. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 1-8.
    271. Adult medulloblastoma, from spongioblastoma cerebelli to the present day. ONCOLOGY (United States). 26.
    272. Using CSF as an internal quality assurance tool in diffusion tensor imaging studies of brain tumor.
    273. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma. Journal of Neuro-Oncology. 126:309-316.
    274. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One. 9.
    275. Immune checkpoint blockade as a potential therapeutic target. Neuro-Oncology. 18:1357-1366.
    276. Erratum. Journal of Neuro-Oncology. 113:151.
    277. Melanoma central nervous system metastases. Pigment Cell and Melanoma Research. 29:627-642.
    278. Erratum. Neuro-Oncology. 6:172.
    279. Toward precision medicine in glioblastoma. Neuro-Oncology. 17:1051-1063.
    280. Targeted therapeutic strategies for relapsed disease. 29-40.
    DE GROOT's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (795)
    Co-Authors (137)
    Similar People (60)
    Same Department Expand Description